Cullen/Frost Bankers’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$355K Buy
1,580
+39
+3% +$9.72K ﹤0.01% 472
2025
Q4
$371K Buy
1,541
+1,003
+186% +$257K ﹤0.01% 467
2025
Q3
$147K Sell
538
-37
-6% -$10.1K ﹤0.01% 585
2025
Q2
$148K Buy
575
+147
+34% +$35.1K ﹤0.01% 570
2025
Q1
$95.8K Hold
428
﹤0.01% 615
2024
Q4
$97.9K Buy
+428
New +$103K ﹤0.01% 604
2024
Q3
Sell
-535
Closed -$102K 1352
2024
Q2
$102K Sell
535
-463
-46% -$93.9K ﹤0.01% 585
2024
Q1
$198K Hold
998
﹤0.01% 483
2023
Q4
$172K Hold
998
﹤0.01% 502
2023
Q3
$148K Sell
998
-800
-44% -$145K ﹤0.01% 549
2023
Q2
$393K Sell
1,798
-6
-0.3% -$1.34K 0.01% 416
2023
Q1
$395K Hold
1,804
0.01% 416
2022
Q4
$375K Hold
1,804
0.01% 421
2022
Q3
$394K Buy
1,804
+6
+0.3% +$1.37K 0.01% 415
2022
Q2
$377K Hold
1,798
0.01% 415
2022
Q1
$436K Hold
1,798
0.01% 419
2021
Q4
$468K Hold
1,798
0.01% 412
2021
Q3
$474K Hold
1,798
0.01% 398
2021
Q2
$443K Hold
1,798
0.01% 418
2021
Q1
$349K Buy
1,798
+712
+66% +$143K 0.01% 441
2020
Q4
$231K Sell
1,086
-3
-0.3% -$598 0.01% 474
2020
Q3
$187K Buy
1,089
+1,086
+36,200% +$201K ﹤0.01% 483
2020
Q2
$1K Buy
+3
New +$491 ﹤0.01% 1073
2020
Q1
Sell
-93
Closed -$14K 1006
2019
Q4
$14K Hold
93
﹤0.01% 856
2019
Q3
$13K Hold
93
﹤0.01% 797
2019
Q2
$11K Sell
93
-34
-27% -$3.77K ﹤0.01% 826
2019
Q1
$13K Buy
+127
New +$13.1K ﹤0.01% 725

Other funds holding RMD

Cullen/Frost Bankers's RMD Position: Q1 2026 in Review

Cullen/Frost Bankers increased its ResMed (RMD) stake by 2.5% in Q1 2026, buying an estimated $9.72K and bringing the position to 1,580 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #472.

Cullen/Frost Bankers first reported a position in RMD in Q1 2019 and has held it in 27 quarters since. The position peaked at $474K in Q3 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Cullen/Frost Bankers held 1,580 shares of ResMed worth $355K as of Q1 2026.
  • Cullen/Frost Bankers bought 39 ResMed shares in Q1 2026, an estimated $9.72K.
  • ResMed made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #472 holding.
  • Cullen/Frost Bankers first reported a position in ResMed in Q1 2019 and has held it in 27 quarters since.
  • Cullen/Frost Bankers's ResMed position peaked at $474K in Q3 2021.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.